Leonard B. Seeff, M.D.
National Institutes of Diabetes, Digestive
and Kidney Diseases
National Institutes of Health

PLACE/DATE OF BIRTH: Johannesburg, South Africa
February 10, 1936

CITIZENSHIP: United States

OFFICE: National Institutes of Diabetes, Digestive
and Kidney Diseases
National Institutes of Health
31 Center Drive #9A18
Bethesda, Maryland 20892-2560
301-435-3338
301-496-2830 facsimile
Seeffl@extra.niddk.nih.gov
and
Veterans Affairs Medical Center 50 Irving Street, NW
Washington, DC 20422
202-745-8452
202-745-8184 facsimile
SEEFF.LEONARD_(GI)@WASHINGTON.VA.GOV e-mail

DEGREES: M.B., B.Ch. (equivalent to M.D.)
University of the Witwatersrand
Johannesburg, South Africa; 1961.

MEDICAL TRAINING:
INTERNSHIP: University of the Witwatersrand Hospitals
(Johan-nesburg General & Hospi-tal Coronation) Johannes-burg, South Africa; 1961-63
Mt. Sinai Hospital, Chicago, Illinois; 1964-65

MEDICAL RESIDENCY: University of the Witwatersrand Hospitals
Johannesburg General, Coronation, Baragwanath),
Johannesburg, South Africa; 1963-64
Veterans Administration Medical Center,
Washington, DC; 1966-77

FELLOW IN GI/HEPATOLOGY:
Mt. Sinai Hospital, Chicago, IL and
Veterans Administration Medical Center,
Washington, DC; 1965-66HOSPITAL APPOINTMENTS:

Research Associate, Liver & Metabolic Research, 1967-68
Veterans Administration Medical Center, Washington, DC

Assistant Chief, Hepatology Section, 1969-71
Veterans Administration Medical Center, Boston, MA

Assistant Chief, Medical Service, 1971-79
Veterans Administration Medical Center, Washington, DC

Chief, Gastroenterology/Hepatology/Nutrition Section 1979-1998
Veterans Administration Medical Center, Washington, DC

Co-Director, Combined Veterans Administration 1985-1998
Georgetown University, Gastroenterology and Hepatology Training Program
Washington, DC

Co-Director, Combined Veterans Administration 1986-1998
Georgetown University/ National Institutes of Health

Gastroenterology and Hepatology Training Program
Senior Scientist for Hepatitis C Research 1998-

National Institutes of Diabetes, Digestive and Kidney Diseases
National Institutes of Health, Bethesda Maryland

PROFESSIONAL SOCIETIES:
American Association for the Study of Liver Diseases
International Association for the Study of the Liver
American Federation for Clinical Research

PROFESSIONAL ORGANIZATIONS:
American College of Gastroenterology, Fellow

ACADEMIC POSITIONS:
Instructor in Medicine, Chicago Medical School, 1965-66
Chicago, IL

Instructor in Medicine, The George Washington 1967-68
University School of Medicine, Washington, DC

Assistant Professor of Medicine, Boston University 1968-71
School of Medicine, Boston, MA.

Assistant Professor of Medicine, Georgetown University 1971-76
School of Medicine, Washington, D.C.

Associate Professor of Medicine, Georgetown University 1976-84
School of Medicine, Washington, D.C.

Professor of Medicine, Georgetown University 1984-present
School of Medicine, Washington, D.C.

AWARDS:
Elvehjem Memorial Award (presented to outstanding person in the field of clinical medicine and
research annually by the Wisconsin Society of Internal Medicine) Milwaukee, Wisconsin. 1980
Korean Society of Gastroenterology Award 1986
Gastroenterology Association of Jamaica Award 1987
Vicennial Gold Medal, Georgetown University 1991
Teacher of the Year, George Washington University 1993
National Academy of Clinical Biochemistry, Special award for outstanding research and contribution to clinical biochemistry 1999
Vietnam Veterans of America: Lifetime Achievement Award for work on hepatitis C 2002

NAMED LECTURES:
3rd Annual Hyman J. Zimmerman Lecture, AFIP, Washington, D.C.
Mizne Memorial Lecture, The Sir Mortine B. Davis Jewish General Hospital, Montreal, Canada.
Elsevier Science Publishers Lectureship 1995
Leon Schiff Memorial Lecture, AASLD: Outcomes Research:
The Hepatitis C Story. 1995
Leon Schiff Lecture, University of Cincinnatti (November 1996)
"The Natural History of Hepatitis C"
Charles Drew Biomedical Institute of the American Red Cross
Lectureship: Patients infected with HCV- their future from a health perspective. California Blood Bank Society 1999

COMMITTEES:
VA Hospital Committees:
Research and Development Committee 1976,79,81,97
Chairman, Research and Development Committee 1980
Chairman, Infectious Diseases Committee 1971
Library Committee 1976-86
AIDS Committee 1986
Search Committee, Chief of Nephrology 1988
Search Committee, Chief of Staff 1991
Search Committee, Chief of Library Service 1991

Georgetown University Committees:
Chairman, Search Committee, Chief of GI 1985
Committee for Dean's Prize for Biomedical Research 1988,89
Member, Committee on Appointments and Promotions 1992-present
Member, Research Planning and Operations Committee 1992

NIH Committees:
NIH Ad Hoc Committee to assess impact of ALT screening of blood donors on the incidence of non-A, non-B post- transfusion hepatitis. 1981
Advisory Committee, National Heart, Lung and Blood Institutes 1983-87
Policy Board, NHLBI AIDS Protocol and Data Monitoring Committee 1984-1990
Liver Tissue Procurement and Distribution System (LTPADS) NIAMDD. 1987-1995
Data Monitoring Committee, NIDDK Thymosin Treatment for Chronic Hepatitis C 1991- Data Monitoring Committee, NIDDK Timolol for Prevention of Variceal Bleeding. 1993-
NHLBI Serum Repository Monitoring Committee 1997-

VA Central Office Committees:
Executive Committee, VA Cooperative Study of Alcoholic Hepatitis. 1978-1982
VA Representative on National Digestive Disease Advisory Board 1981-1994
VA Ad Hoc Committee on hepatitis vaccine use the VA Gastroenterology Advisory Group 1982-1983
VA Liver Transplant Committee 1986-

American Assoc. for the Study of Liver Diseases Committees:
American Registry of Pathology, alternate 1981-1989
American Registry of Pathology, member 1990-
Training and Education Committee 1983
Chairman, Training and Education Committee 1988
Nominations Committee 1988, 2000
Nomenclature of Chronic Hepatitis (IASL) 1993
Practice Guidelines Committee 1996-1998
Councillor-At-Large 1997-
Food and Drug Administration, Committee on Devices Center for Drug Evaluation and Research 1995-present
National Hemophilia Foundation, Medical and Scientific Advisory Council 1995-

World Federation of Hemophilia, Advisor on Hepatitis 2001-Policy Board, American Red Cross Study to evaluate
washed and deglycerolized frozen red cells as a means of reducing the incidence of post transfusion hepatitis 1975-1978
American Blood Commission; Ad Hoc Committee to review
GAO report on hepatitis from blood transfusions 1975
Transfusion Task Force, American Blood Commission 1975-1979
Medical and Chirurgical Society of the State of Maryland, Ad Hoc Committee on viral hepatitis 1976
Expert Group on Viral Hepatitis, Lister Hill Center's Information Transfer Program, National Library of
Medicine. 1986
Hepatitis Foundation International, Vice-President 1995-

EDITORIAL BOARD:
Hellenic Journal of Gastroenterology 1988-present
Seminars in Liver Disease 1999-
Minerva Gastroenterologica e Dieteloica 2000-

OTHER PROFESSIONAL ACTIVITIES:
Consultant in Hepatology, DC General Hospital, Wash. DC 1974-1984
Consultant in Hepatology, National Institutes of Health 1984-
Coordinator, Physical Diagnosis Course for Georgetown
University Medical Students at the V.A. Medical Center,
Washington, D.C. 1975-1982
Reviewer of numerous grant proposals for NIAID, NHLBI, NCI, NIDDK, FDA, etc.
Numerous NIH Site Visits
Reviewer for numerous national/international scientific medical journals
Abstract reviewer for AASLD annual meetings 1982-1983,1988,1995-2000
Reviewer for OSHA Instruction Guidelines CPL 2-236,
Office of Occupational Medicine, "The Risks of Hepatitis B Infection for Workers in the Health Care
Delivery System and Suggested Methods for Risk Reduction" 1983
Reviewer for V.A. Physicians' Guide for Disability Evaluation Examination 1985
Advisory Board, Gastroenterology Section, Children's Hospital National Medical Center 1989-present Consultant, Center for Disease Control 1990-present
Consultant, Food & Drug Administration 1990-present
Chairman, Inter-Agency HCV Working Group 1998-

NIH Consensus Development Conferences
Infectious disease testing for blood transfusions Speaker January 9-11,1995
Management of Hepatitis C Planning Committee and Speaker March 24-26,1997

Other NIH Conferences
Organized and spoke at meeting, entitled: Complementary and Alternative Medicine in Chronic Liver Disease August, 1999
Visiting Professor
Invitations to numerous Academic Centers

GRANTS:
Veterans Administration Merit Review, FY 1984 $ 26,675
Veterans Administration Merit Review, FY 1985 $ 28,036
Veterans Administration Merit Review, FY 1986 $ 24,768
Veterans Administration Merit Review, FY 1987 $ 43,172
Veterans Administration Merit Review, FY 1988 $ 16,838
Yellow Fever Vaccine Study, National Cancer Institute, FY 1984 $ 47,121
Yellow Fever Vaccine Study, National Cancer Institute, FY 1985 $ 58,415
Natural History Study of Post-Transfusion Non-A, Non-B Hepatitis, National Heart, Lung, and Blood Institute, 1987-1992. $4,800,000
ICN Pharmaceuticals, Los Angeles, California 1992-1993 $ 270,000
Hoechst-Roussel Pharmaceuticals, New Jersey 1993- $ 211,000
Natural History of Transfusion-Associated Non-A, Non-B Hepatitis. National Heart, Lung, and Blood
Institute, 1993-1998 $4,700,000
Long-term follow-up of Air-Force recruits with hepatitis C virus infection; National Cancer Institutes, 1994-1995 $ 95,000
Long-term follow-up of Air-Force recruits with hepatitis C virus infection; National Institutes of Allergy and
Diseases, 1995-1996 $ 211,000
ICN Pharmaceuticals, Los Angeles, Ca., 1995 $ 8,000
Glaxo Foundation, Lamivudine for Treatment of Chronic Hepatitis B $ 110,000
Schering-Plough Research Institute: Intron A plus Ribavirin for treatment of chronic hepatitis C $ 30,000
Long-term follow-up of parenteral drug abusers; National Institutes of Drug Abuse, NIH $ 350,000

BIBLIOGRAPHYJOURNAL PUBLICATIONS:
1. Seeff LB, Levitsky J, Tillman PW, Perou ML, Zimmerman HJ: Histopathology of the liver in Down's Syndrome. Amer. J. Dig. Dis. 1967; 12:1102-1113.
2. Seeff LB, Hendler ED, Hosten AO, Shalhoub RS: Ethylene glycol poisoning. Med. Ann. D.C. 1979; 39:31-35.
3. Kendler J, Bowry S, Seeff LB, Zimmerman HJ: Effect of chlorpromazine on the function of the perfused isolated liver. Biochem. Pharmacol. 1971; 20:243-9-2445.
4. Phornphutkul KS, Anuras S, Koff RS, Seeff LB, Mahler DL, Zimmerman HJ: Causes of increased plasma creatine kinase activity after surgery. Clin. Chem. 1974; 20:340-342.
5. Seeff LB: Hepatitis in the drug abuser. Med. Clin. N. Amer. 1975; 59:843-848.
6. Seeff LB, Zimmerman HJ, Wright EC, Schiff ER, Kiernan T, Leevy CM, Tamburro CH, Ishak KG: Hepatic disease in asymptomat-ic parenteral narcotic drug abusers. A Veterans Administra-tion Collaborative Study. Am. J. Med. Sci. 1975; 270:41-47.
7. Seeff LB, Wright EC, Zimmerman HJ, McCollum RW, Members of VA Hepatitis Cooperative Studies group. VA Cooperative study of post-transfusion hepatitis, 1969-1974: incidence and characteris-tics of hepatitis and responsible risk factors. Am. J. Med. Sci. 1975; 270:355-362.
8. Seeff LB, Zimmerman HJ, Wright EC, Felsher BF, Finkelstein JD, Garcia-P-ont P, Greenlee HB, Dietz AA, Hamilton J, Koff RS, Leevy CM, Kiernan T, Tamburro CH, Schiff ER, Vlahcevic Z, Zemel R, Zimmon DS, Nath N: Efficacy of hepatitis B immune serum globulin after accidental exposure. Lancet 1975; 2:939-941.
9. Koch MJ, Seeff LB, Crumley CE, Rabin L, Burns WA: Quinidine hepatotox-icity. A report of a case and review of the literature. Gastroenter-ology 1976; 70:1136-1140.
10. Alter HJ, Seeff LB, Kaplan PM, McAuliffe VJ, Wright EC, Gerin HJ, Purcell RH, Holland PV, Zimmerman HJ: Type B hepatitis: the infec-tivity of blood positive for e antigen and DNA polymerase after acci-dental needlestick exposure. N. Engl. J. Med. 1976; 295:909-913.
11. Berk PD, Jones A, Plotz PH, Seeff LB, Wright EC: Corticosteroid therapy for chronic active hepatitis. Ann. Int. Med. 1976; 85:523-525.
12. Seeff LB, Zimmerman HJ, Wright EC, Finkelstein JD, Garcia-Pont P, Greenlee HB, Dietz AA, Leevy CM, Tamburro CH, Schiff ER, Schimmel EM, Zemel R, Zimmon DS, McCollum RW: A randomized double-blind controlled trial of the efficacy of immune serum globulin for the prevention of post-transfusion hepatitis. Gastroenterology 1977; 72:111-121.
13. Lipman TO, Seeff LB, Dobbins WO, III: Chronic active hepatitis: Prolonged survival without treatment. Amer. J. Dig. Dis. 1977; 22:43-48.
14. Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff LB, Levy LL: Comparison of lactulose and neomycin in the treat-ment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroen-terology 1977; 72:573-583.
15. Barker LF, Knodell RG, Seeff, LB: High titer and standard immune globulin: can they prevent hepatitis B? Mod. Med. 1977; 40-42.
16. Seeff LB, Wright EC: International Forum: How frequent is post-transfusion hepatitis after the introduction of 3rd genera-tion donor screening for hepatitis B? What is its probable nature? Vox Sang. 1977; 32:346-363.
17. Wright EC, Seeff LB, Berk PD, Jones A, Plotz PH: Treatment of chronic active hepatitis: An analysis of three controlled trials. Gastroenter-ology 1977; 73:1422-1430.
18. Seeff LB, Hoofnagle JH: Chronic hepatitis in hemophilia. Ann. Int. Med. 1977; 86:818-820.
19. Bales ZB, Patterson JE, Hoofnagle JH, Seeff LB: Variation in gamma counter efficien-cy used in radioimmunoassay testing for hepatitis B surface antigen and antibody. Transfusion 1978; 18:91-93.
20. Seeff LB, Wright EC, Zimmerman HJ, Alter HJ, Dietz AA, Felsher BF, Finkelstein JD, Garcia-Pont P, Gerin JL, Greenlee HB, Hamil-ton J, Holland PV, Kaplan PM, Kiernan T, Koff RS, Leevy CM, McAuliffe VJ, Nath N, Purcell RH, Schiff ER, Schwartz CC, Tamburro CH, Vlahcevic Z, Zemel R, Zimmon DS: Type B Hepatitis after Needlestick Exposure: Prevention with hepatitis B immune globulin. Ann. Int. Med. 1978; 88:285-293.
21. Tabor E, Gerety RJ, Drucker JA, Seeff LB, Hoofnagle JH, Jackson DR, April M, Barker LF, Pineda-Tamondong G: Transmission of Non-A, Non-B hepatitis from man to chimpan-zee. Lancet 1978; 1:463-466.
22. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman HJ, and the Veterans Administration Hepatitis Cooperative Study Group. Type B hepati-tis after transfusion with blood containing antibody to hepatitis B core antigen. N. Engl. J. Med. 1978; 298:1379,1383.
23. Seeff LB, Zimmerman HJ: Treat or don't treat asymptomatic chronic active hepatitis. Practical Gastroenterology 1978; 2:30-34.
24. Tabor E, April M, Seeff LB, Gerety RJ: Acute non-A, non-B hepatitis: prolonged presence of the infectious agent in blood. Gastroenterology 1979; 76:680-684.
25. Seeff LB, Hoofnagle JH: Immunoprophylaxis of viral hepatitis. Gastroenter-ology 1979;77:161-182.
26. Zimmerman HJ, Utili R, Seeff LB, Hoofnagle JH: Jaundice due to bacterial infection. Gastroenterology 1979; 77:362-374.
27. Tabor E, April M, Seeff LB, Gerety RJ: Acquired immunity to human non-A, non-B hepatitis. Cross challenge of chimpanzees with three infectious sera. J. Infect. Dis. 1979; 140:789-793.
28. Tabor E, Seeff LB, Gerety RJ: Lack of susceptibility of marmo-sets to human non-A, non-B hepatitis. J. Infect. Dis. 1979; 140:794-797.
29. Hoofnagle JH, Seeff LB, Bales ZB, Wright EC, Zimmerman HJ, and VAMC Study Group. Passive-active immunity from hepatitis B immune globulin. Ann. Int. Med. 1979; 9l:813-818.
30. Hoofnagle JH, Blake J, Bales ZB, Seeff LB: Lack of transmission of type B hepatitis by fiberoptic upper endoscopy. J. Clin. Gastroen-terology 1980; 2:65-69.
31. Tabor E, Peterson DA, April M, Seeff LB, Gerety RJ: Transmis-sion of human non-A, non-B hepatitis to chimpanzees following failure to transmit GB agent hepatitis. J. Med. Virol.1980; 5:l03-108.
32. Tabor E, Seeff LB, Gerety RJ: Chronic non-A, non-B hepatitis carrier state:
Transmissi-ble agent documented in one patient over a six-year period. New Engl.J. Med. 1980;303:140-143.
33. Licht H, Seeff LB, Zimmerman HJ: The apparent potentiation of acetaminophen hepatotoxicity by alcohol. Ann. Int. Med. 1980; 92:511-512.
34. Seeff LB: Immunoprophylaxis and treatment of viral hepatitis B. Sem. Liver Dis. 1981; 1:69-80.
35. Seeff LB: Drug-induced chronic liver disease with emphasis on chronic active hepatitis. Sem. Liver Dis. 1981; 1:104-115.
36. Seeff LB. Drug-induced chronic hepatitis. Current Concepts Gastroenterol 1984; 3-8.
37. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Buskell-Bales Z: Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann. Int. Med. 1981; 94:744-748.
38. Seeff LB:Serologic markers in hepatitis B virus infection. Internal Medicine for the Specialist 1981; 2:41-48.
39. Al-Kawas AF, Seeff LB, Berendson RA, Zimmerman HJ, Ishak KG: Allopurinol hepatotoxicity. Report of two cases and review of the literature. Ann. Int. Med. 1981; 95:588-590.
40. Brook I, Altman RS, Loebman WW, Seeff LB: Measurement of lactate in ascitic fluid: An aid in the diagnosis of peritonitis with particular relevance to spontaneous bacterial peritonitis of the cirrhotic. Dig. Dis. Sci. 1981; 26:1089-1094.
41. Seeff LB, et al: Should donors with a history of jaundice still be rejected? International Forum. Vox. Sang. 1980; 41:110-127.
42. Seeff LB: The role of corticosteroids in chronic hepatitis. Int. Med. for the Specialist 1983; 4:126-131.
43. Cuccherini B, Nussbaum SJ, Seeff LB, Lukacs L, Zimmerman HJ: Stability of aspartate and alanine aminotransferase activities. J. Lab. Clin. Med. 1983; 102:370-376.
44. Seeff LB, Koff RS: Passive and active immunoprophylaxis of hepatitis B. Gas-troen-terol-ogy 1984; 86:958-981.
45. Rubel LR, Rabin L, Seeff LB, Licht H, Cuccherini BA: Does primary biliary cirrhosis in men differ from primary biliary cirrhosis in women? Hepatology 1984, 4:671-677.
46. Ponzetto A, Hoofnagle JH, Seeff LB: Antibody to the hepatitis B virus associated delta agent in immune serum globulins. Gastro-enterology 1984; 87:1213-1216.
47. Ponzetto A, Seeff LB, Buskell-Bales Z, Ishak KG, Hoofnagle JH, Zimmerman HJ, Purcell RH, Gerin JL, and the Veterans Administra-tion Hepatitis Cooperative Study Group: Hepatitis B markers in United State drug addicts with special emphasis on the delta hepatitis virus. Hepatology 1984; 4:1111-1115.
48. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg SR, Kiernan T, Seeff LB, Sorrell M, Tamburro CH, Weisner R, Zetterman R, Chedid A, Drew T, Rabin L: Short-term and long-term survival in pa-tients with alcoholic hepatitis treated with oxandrolone and predniso-lone. N. Engl. J. Med. 1984; 311:1464-1470.
49. Seeff LB: Drug-induced chronic hepatitis. Current Concepts in Gastroenterology, 1984; 9:3-8.
50. Ihde DC, Matthews MJ, Makuch RW, McIntire KR, Eddy JL, Seeff LB: Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy: identification of two groups of patients with prospects for prolonged survival. Am. J. Med. 1985; 78:399-406.
51. Hoofnagle JH, Ponzetto A, Mathiesen LR, Waggoner JG, Buskell-Bales Z, Seeff LB: Serological diagnosis of acute viral hepatitis. Dig. Dis. Sci. 1985; 30:1022-1027.
52. Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB: Acetamino-phen hepato-- toxicity in alcoholics: A therapeutic misadventure. Ann. Int. Med. 1986; 104:399-404.
53. Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Zetterman R, Chedid A, Chen T, Rabin L: VA cooperative study on alcoholic hepatitis II: Prognostic significance of protein-calorie malnutrition. Amer. J. Clin. Nutr. 1986; 43:213-218.
54. Chedid A, Mendenhall CL, Tosch T, Chen T, Rabin L, Garcia-Pont P, Goldberg SJ, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Weesner RE, Zetterman R, and the Veterans Administration Cooperative Study of Alcoholic Hepatitis: Significance of megamitochondria in alcoholic liver disease. Gastroenterology 1986; 90:1858-1864.
55. Goldberg S, Mendenhall C, Anderson S, Garcia-Pont P, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Weesner R, Zetterman R, Chedid A, Chan T, Rabin L, and the V.A. Cooperative Study Group 119. V.A. Cooperative Study on Alcoholic Hepatitis IV. The signifi-cance of clinically mild alcoholic hepatitis describing the population with minimal hyperbili-
rubi-nemia, Amer. J. Gastroenter-ology 1986; 8l:1029-1034.
56. Hoofnagle JH, Davis GL, Pappas C, Hanson RG, Peters M, Avigan MI, Waggoner JG,Jones EA, Seeff LB: A short course of predisone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann. Int. Med. 1986; 104:12-17.
57. Seeff LB, Koff, RS: Evolving concepts of clinical and serologic consequences of hepatitis B virus infection. Sem. Liver Dis. 1986; 6:11-22.
58. Eichberg JW, Seeff LB, Lawler DA, Buskell-Bales Z, Ishak K, Hoofnagle JH, Goldstein AL, Langloss JM: Effect of thymosin immunostimulation with and without corticoste-roid immunosuppres-sion on chimpanzee hepatitis B carriers. J. Med. Virol. 1987; 21:25-37.
59. Seeff LB, Beebe GW, Hoofnagle JH, Norman JE, Buskell-Bales Z, and the VA Cooperative Studies Group. A serologic follow-up of the 1942 epidemic of post-vaccinal hepatitis in the United States Army. N. Engl. J. Med. 1987; 316:965-970.
60. Seeff LB: The American Association for the Study of Liver Diseases. Presentation of the Distinguished Achievement Award to Hyman J Zimmerman, M.D. Hepatology 1987; 213-215.
61. Seeff LB, Dienstag JL: Transfusion-associated hepatitis: Where do we go from here? Gastroenterology 1988; 95:530-533.
62. Seeff LB: The gold standard serologic marker for hepatitis B virus infectivity (Hepatology Elsewhere). Hepatology 1988; 8:1711-1713.
63. Seeff LB: Transfusion-associated hepatitis B: past and present. Transfusion Med Rev. 1988; 2:204-214.
64. Lemley DE, de Lacey LM, Seeff LB, Ishak KG, Nashel DJ: Azathioprine induced hepatic veno-occlusive disease in rheumatoid arthritis. Ann. Rheum. Dis. 1989; 48;342-346.
65. Cupps TR, Hoofnagle JH, Ellis RW, Miller WJ, Seeff LB, Guerrera A, Gerin JC, Haas-Smith SA: In vitro immune responses to hepati-tis B virus in humans. J. Clin Immunol 1989; 9:229-241.
66. Seeff LB: Non-A, non-B hepatitis. Current Opinion in Gastroen-terology 1989; 5:378-387.
67. Seeff LB: Non-A, non-B hepatitis. Viewpoints on Dig. Dis. 1989;21:9-12.
68. Diehl AM, Seeff LB: Treatment of chronic hepatitis B. Practical Gastroenterology 1989; 13:53-61.
69. Lewis JH, Ranard RC, Caruson A, Jackson LK, Mullick F, Ishak KG, Seeff LB, Zimmerman HJ. Amiodarone hepatotoxicity: Prevalence and clinicopatho-logic correlations among 104 patients. Hepatology 1989; 9:679-685.
70. Lewis JH, Mullick F, Ishak KG, Ranard RC, Ragsdale B, Perse MS, Rusnock EJ, Wolke A, Benjamin, SB, Seeff LB, Zimmerman HJ: Histopathologic analysis of suspected amiodarone hepatotoxicity. Human Pathology 1990; 21:59-67.
71. Biggar RJ, Buskell-Bales Z, Yakshe PN, Caussy D, Gridley G, Seeff, LB. Antibody to human retroviruses among drug abusers in three East Coast American cities, 1972-1976. J. Infect. Dis. 1991; 163:57-63.
72. Mendenhall CL, Seeff LB, Diehl AM, Ghosn SJ, French SW, Gartside PS, Rouster SD, Buskell-Bales Z, Grossman CJ, Roselle GA, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan TW, Tamburro CH, Zetterman R, Chedid A, Chen T, Rabin L, and the VA Cooperative Study Group (No 119). Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepati-tis and cirrho-sis: Their prevalence and clinical relevance. Hepatology 1991; 14:581-589.
73. Knodell RG, Davis GL, Seeff LB, Alter HJ. HCV:closing the circle of an elusive agent.
Contemporary Gastroenterol 1991; May/June, 58-71.
74. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion associated non-A, non-B hepatitis. N. Engl. J. Med. 1992; 327:1906-1911.
75. Seeff LB. In Consultation: Is blood transfusion a red herring or a clue to the cause of cirrhosis? J Crit Illness 1992;7:1211-1212.
76. Norman JE, Beebe GW, Hoofnagle JH, Seeff LB. Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army. Hepatology 1993;18:790-797.
77. Seeff L.B.: Is the long-term outcome after posttransfusion hepatitis benign? (Selected Summaries). Gastroenterolo-gy 1993;105:1257-1258.
78. Seeff LB, Alter, HJ: Spousal Transmission of the Hepatitis C Virus? (editorial) Ann. Int. Med. 1994;120:807-809
79. Seeff LB, Natural history of viral hepatitis, type C. Sem.Gastrointestinal Dis. 1995;6:20-27.
80. Seeff L.B.: Foreword, Hepatitis C. Sem Liver Dis 1995;15:1-4.
81. Seeff L.B.: Long-term outcome of hepatitis C virus infection. Liver Update Function and Disease 1995;9:1-2.80.
82. Tedeschi V, Seeff LB: Diagnostic tests for hepatitis C: Where are we now? (editorial) Ann.Intern Med. 1995;123:383-385.
83. Strader DB, Seeff, LB: Implications of the natural history of hepatitis C infection. Contemp. Int. Med.1995;7:46-52.
84. Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. Eur J
Gastroenterol Hepatol 1996;8:324-328.
85. Koff RS, Seeff LB: Economic modeling of treatment in chronic hepatitis B and chronic hepatitis C: promises and limitation (editorial). Hepatology 1995;22:1880-1882.
86. Duffy LF, Kerzner B, Seeff LB, Barr SB, Soldin SJ. Preliminary assessment of glycine conjugation of paraaminobenzoic acid as a quantitative test of liver function. Clin Biochem 1995;28:527-530.
87. Strader DB, Seeff LB: New hepatitis A vaccines and their role in prevention. Drugs 1996;51:359-366.
88. Strader DB, Seeff LB. Immunization for viral hepatitis. Current Opinion in Gastroenterology 1996;12:224-230.
89. Seeff LB. An update on viral hepatitis. Hemaware 1977;2:9-12.
90. Bodenheimer Jr HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter study. Hepatology 1977;26:473-477.
91. Seeff LB. Natural history of hepatitis C. Hepatology (Supplement) 1997;26:21S-2
92. Seeff LB Progression of chronic hepatitis C: it’s the fibrosis, not the necrosis!
(Hepatology Elsewhere) Hepatology 1997
93. Seeff LB. The natural history of chronic hepatitis C virus infection. Clin Liv Dis 1997; 1:587-602.
94. Seeff LB Chronic hepatitis C : beware the older drinking male : fibrosis progression
beckons ! (Hepatology Elsewhere) Hepatology 1997 ;26 :1074-1076.
95. Kerr GS, Rofail M, Lewis JH, Kumar P, Seeff LB. Prevalence of hepatitis C virus associated cryoglobulinemia at a Veterans Hospital. J Rheum 1997;24:2134-2138.
96. Seeff LB: The natural history of hepatitis C – a quandary. Hepatology 1998;28:1710-1712
97. Seeff LB: Dilemma of the natural history of hepatitis C. J Gastroenterol Hepatol 1999;14:199-201.
98. Fiel MJ, Schiano TD, Guido M, Thung SN, Lindsay KL, Davis GL, Lewis JH, Seeff LB,
Bodenheimer HC, Jr. Increased iron deposition resulting from treatment of chronic
hepatitis C with ribavirin. Am J Clin Path 2000;113:35-39.
99. Seeff LB. Natural history of hepatitis C. Am J Med 1999;107(6B):10S-15S.
100.Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, Johnson LD,Lee SR, Kaplan EL. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 200O;132:105-111.
101. Seeff LB. Natural history of hepatitis C. In: Liang TJ, moderator. Pathogenesis, natural
history, treatment and prevention of hepatitis C. Ann Intern Med 2000;132:299-300.
102. Lemon SM, Layden TJ, Seeff LB, Suzuki H, Nishioka K, Mishiro S, Johnson L. The 20th United States-Japan Joint Hepatitis Panel Meeting. Hepatology 2000;31:800-806.
103. Branch AD, Seeff LB. Foreword. Seminars Liv Dis 2000;20:iii-v
104. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Seminar Liv Dis 2000, 20:17-35.
105. Sulkowski MS, Mast EE, Seeff LB, Thomas DL. Hepatitis C virus as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30:S77-84.
106. Branch AD, Seeff LB. Afterword: HCV in the decades ahead. Sem Liv Dis 2000;20:233-237.
107. Seeff LB. Obituary: Hyman J. Zimmerman, MD JAMA 2000;283:1-2.
108. Seeff LB. Why is there such difficulty in defining the natural history of hepatitis C. Transfusion 2000; 40:1161-1164.
109. Rao MN, Liu Q-H, Marmillot P, Seeff LB, Strader DB, Lakshman MR. High –density lipoproteins from human alcoholics exhibit impaired reverse cholesterol transport function. Matabolism 2000; 49:1406-1410.
110. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem
2000;46:2027-2049.
111. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin Chem 2000;46:2050-2068.
112. Seeff LB. Strategies for assessing the long-term consequences of hepatitis C virus infection. Minerva Gastroenterologica e Dietologica 2000;46:207-216.
113. Harris DR, Gonin R, Alter HJ, Wright EC, Buskell ZJ, Hollinger FB, Seeff LB, for the National Heart, Lung and Blood Institute. The relationship of acute transfusion associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001;134:120-124.
114. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Cain CMB, Buskell ZJ, Ishak KG, Iber FL, Toro D, Samanta A, Koretz RL, Perrillo R, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 2001;33:455-463.
115. Strader DB, Seeff LB. Hepatitis C: A brief clinical overview. ILAR Journal 2001;42:107- 116.
116. Hyams KC, Riddle J, Rubertone M, Trump D, Alter MJ, Cruess DF, Han X, Nainam OV, Seeff LB, Mazzuchi JF, Bailey S. Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. Amer J Epidemiol 2001;153:764-770.
117. Lin HJ, Seeff LB, Barbosa L, Hollinger FB. Occurrence of identical hypervariable region 1 sequences of hepatitis C virus in transfusion recipients and their respective blood donors: divergence over time. Hepatology 2001;34:424-429.
118. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology 2001;34:595-603.

BOOK CHAPTERS:
1. Hyman J. Zimmerman and Leonard B. Seeff: Enzymes in hepatic disease. In Diagnostic Enzymology, Eugene L. Coodley, (ed). Lea and Febiger, Philadelphia 1970, pp.1-38.
2. Hyman J. Zimmerman and Leonard B. Seeff: Hepatitis associated with drug abuse, In Frontiers of Internal Medicine, 12th Int. Cong. Inter-nal Med. Karger and Basel, Tel Aviv, 1974, pp.210-214.
3. LB Seeff, HJ Zimmerman, EC Wright, ER Schiff, CH Tamburro, CM Leevy, KG Ishak : VA Collaborative Study in Liver Disease in Drug Addicts. Preliminary report, In Proceedings of the 5th Quadrennial Meeting of the International Association for the Study of the Liver. Karger and Basel, Acapulco, 1974, pp.167-169.
4. Leonard B. Seeff and Hyman J. Zimmerman: Relationship between hepatic and pancreatic diseases. In Progress in Liver Diseases, Hans Popper and Fenton Schaffner (eds). Grune and Stratton, New York and London, 1976, pp.590-608.
5. Leonard B. Seeff and Jay Hoofnagle: Acute and chronic liver disease in hemophilia, In Unresolved Therapeutic Problems in Hemophilia, D.L. Aronson and J.C. Fratantoni (eds). DHEW Publication No. (NIH) 77-1089, Washington, D.C., 1977, pp.55-66.
6. Leonard B. Seeff and Hyman J. Zimmerman: Acute viral hepatitis, In - Current Therapy-, HF Conn (ed). W.B. Saunders, Philadelphia, 1977, pp.384-387.
7. LB Seeff, EC Wright, HJ Zimmerman, JH Hoofnagle, AA Dietz, BF Felsher, PH Garcia-Pont, R J Gerety, HB Greenlee, T Kiernan, CM Leevy, N Nath, ER Schiff, CC) Schwartz, E Tabor, CH Tamburro, Z Vlahcevic, R Zemel, DS Zimmon: Post-transfusion Hepatitis, 1973-1975: A Veterans Admin-istration Cooperative Study. In -Viral Hepatitis-, GN Vyas, SN Cohen, R Schmid (eds). Franklin Institute Press, Philadelphia, 1978, pp.371-381.
8. JH Hoofnagle, LB Seeff, ZB Bales, RJ Gerety, E Tabor: Serologic responses in type B hepatitis. In -Viral Hepatitis-, GN Vyas, R Schmid (eds). Franklin Institute Press, Philadelphia, 1978, pp.219-242.
9. E Tabor, RJ Gerty, JA Drucker, LB Seeff, JH Hoofnagle, M April, G Pineda-Tamond_ong, LF Barker: Experimental transmission and passage of human non-A, non-B hepatitis in chimpanzees. In Viral Hepatitis, GN Vyas, SN Cohen, R Schmid (eds). Franklin Institute Press, Phila-delphia, 1978, pp.419-421.
10. Seeff LB: Chronic viral hepatitis. In Current Chemotherapy and Infectious Diseases. Proceedings of the 11th International Congress of Chemotherapy and the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy. JD Nelson, C Grassi (eds). 1979; 1:7-8.
11. Member of Hepatitis Knowledge Base Expert Panel. The Hepatitis Knowledge Base: A Prototype Information Transfer System. Ann. Int. Med. 93:(1, Supp.l, Part 2) 165-222, 1980.
12. Leonard B Seeff: Post-transfusion hepatitis. In Haemophilia, edited by U. Seligsohn A Rimon, H Horoszowski. Castle House Publications, Tunbridge Wells, 1981; pp.131-139.
13. Leonard B Seeff: Hepatitis in hemophilia: A brief review. In Frontiers in Liver Disease, edited by PD Berk, TC Chalmer. Thieme-Stratton, New York, 1981 pp.231-241.
14. Leonard B Seeff: Prospects for prevention of Non-A, non-B hepatitis. In Non-A Non-B Hepatitis, edited by RJ Gerity. Academic Press, New York, 1981, pp.271-288.
15. Leonard B Seeff: The efficacy of and place for HBIG in the prevention of type B hepatitis. In Viral Hepatitis: 1981 International Sympo-sium, edited by WF Szmuness, HJ Alter, JH Maynard. Franklin Institute Press, Philadelphia, 1982, pp.585-595.
16. Hoofnagle JH, Seeff LB: Natural history of chronic type B hepatitis. In Progress in Liver Disease, Volume VII, edited by H. Popper and F. Schaffner. Grune and Stratton, New York, 1982, pp. 469-479.
17. Leonard B Seeff: Diagnosis, therapy and prognosis of viral hepatitis. In Hepatology: A Textbook of Liver Disease, edited by D Zakim, T Boyer. W.B. Saunders, Philadelphia, 1982, pp.911-971.
18. Benjamin SB, Seeff LB: Natural history and management of "asymp-tomatic" chronic active hepatitis. In Chronic Active Liver Disease, edited by S Cohen, RD Soloway. Churchill Livingstone, New York, 1983, pp.41-50.
19. Seeff LB, Koff RS: Therapy for chronic active hepatitis. In Advances in Internal Medicine, edited by G Stollerman. Year Book Medical Publisher, 1984, pp.109-145.
20. Seeff LB: Should hospital associated needle sticks of unknown source merit prophylaxis with hepatitis B immune globulin as a routine precaution? In Controversies in Gastroenterol-ogy, edited by G. Gitnick. Churchill Livingstone, New York, 1984, pp.185-193.
21. Seeff LB: Closing remarks: Strategies for passive and active prophylaxis. In Viral Hepatitis and Liver Diseases, edited by GN Vyas, JL Dienstag, JH Hoofnagle. Grune and Stratton, New York, 1984, pp.537-541.
22. Seeff LB: Viral hepatitis and its differential diagnosis. In Current Diagnosis edited by RB Conn. W.B. Saunders, 1985, pp.706-712.
23. Seeff LB: Passive immunoprophylaxis. In -Hepatitis B-, edited by RJ Gerety. Academic Press, Orlando, 1985, pp.353-383.
24. Seeff LB: Viral hepatitis in pregnancy. In -Gastrointestinal- -and Hepatic Complications in Pregnancy-, edited by VK Rustgi, JN Cooper. Wiley Medical Publications, New York, 1986, pp.179-199.
25. Seeff LB: Acute Viral Hepatitis. In -Current Therapy in Gastro-enterology and Liver Disease-2-, edited by TM Bayless, BC Decker. Toronto, 1986, pp.380-383.
26. Seeff LB, Wright EC: An overview and appraisal of the Mayo Clinic trial for chronic active hepatitis. In -Chronic Active Hepatitis- -The Mayo Clinic Experience, edited by AJ Czaja, E Rolland Dixon. Marcel Dekker, New York, 1986, 305-340.
27. Seeff LB: Clinical manifestations of delta hepatitis infection. In Viral Hepatitis and the Immunodeficiency Syndrome- edited by VM Villarejos, Trejos Hnos. San Jose, Costa Rica, 1987, 213-221.
28. Seeff LB: Chronic viral hepatitis. In -Clinical Problems in- -Gastroen-terology,- edited by SJ Chobanian and M Van Ness. Little Brown, Boston, 1988, 149-154.
29. Abernathy CO, Stocker JT, Utili R, Seeff LB: Jaundice of system-ic infection. In Current Perspectives in Hepatology: Fest-schrift for Hyman J Zimmerman, M.D.,- edited by Seeff LB and Lewis JH. Plenum Medical, New York, 1989, 337-356.
30. Seeff LB: Diagnosis, therapy, and prevention of viral hepatitis. In Hepatology: A Textbook of Liver Disease, Second Edition, edited by D Zakim and TD Boyer. W.B. Saunders, Philadel-phia, 1990,958-1025.
31. Seeff LB, Dienstag JL: Transfusion-transmitted hepatitis A, B, and D. In Principles of Transfusion Medicine, edited by E Rossi, TL Simon, GS Moss. Williams and Wilkins, Baltimore, 1991, 561-571.
32. Seeff LB, Ishak KG, Gerber MA: Unresolved clinical issues and histo-pathologic and immunopathologic aspects of chronic active hepatitis B and C. In Viral Hepatitis and Liver Disease, edited by F Blaine Hollinger, Stanley M Lemon and Harold S. Margolis. Williams and Wilkins, Baltimore, 1990, 805-813.
33. Mendenhall CL, Seeff LB, Diehl AM, Nelles M, Agius C, Ghosn, French S, Cartside P, Grossman J, Roselle A, Weesner RE: Hepatitis B and C Serologic Markers: Relation-ship to Alcoholic Hepatitis and Cirrhosis. In Viral and Liver Disease, edited by F Blaine Hollinger, Stanley M Lemon and Harold S. Margolis. Williams and Wilkins, Baltimore, 1990, 448-450.
34. Seeff LB: Yellow fever vaccine - associated hepatitis epidemic during World War II: follow-up more than 40 years later. In Epidemiology in Military and Veterans Populations, edited by William F Page. National Academy Press, 1991, 9-17.
35. Hsia PC, Seeff LB: Non-A, non-B hepatitis: Impact of the emergence of the hepatitis C virus. In Advances in Internal Medicine, Volume 37. Stollerman GH, LaMont JT, Leonard JJ, and Siperstein MD (eds). Mosby Year Book, St. Louis, 1992, 197-222.
36. Seeff LB: Acute Viral Hepatitis. In Liver and Biliary Diseases, Kaplowitz N (ed). Williams and Wilkins, Baltimore, 1992, 252-278.
37. Mishra L, Seeff LB: Viral Hepatitis, A through E, complicating pregnancy. In
Gastroen-terology Clinics of North America, Riely CA and Abell Tl (eds). W.B. Saunders, Philadelphia, 1992, 873-887.
38. Alter HJ, Seeff LB: Transfusion-associated hepatitis. In Zuckerman AJ, Thomas HC (eds). Viral Hepatitis: Scientific Basis Clinical Management. Churchill Livingstone, Edinburgh 1993;467-498.
39. Benya RV, Seeff LB. Medical management of ascites, In A pharmacologic approach to
gastrointestinal disoprders, Lewis JH (ed), Williams and Wilkins, Baltimore, 1993:415-
448.
40. Pham DQ, Seeff, LB: Acute hepatitis: management and prevention. In Bayless TM (ed). Current Therapy in Gastroenterology and Liver Diseases, 4th Edition, Mosby, St Louis. 1994;479-483.
41. Koff RS, Seeff LB, Dienstag JL. Transfusion-transmitted hepatitis A,B,and D. In Principles of Transfusion Medicine, 2nd edition. Edited by Ross EC, Simons TC, Moss GS, and Gould SA. Williams and Wilkins, Baltimore 1996; 675-686.
42. Fry SW, Seeff LB, Hepatotoxicity of analgesics and anti-inflammatory agents. In Gastroenterology Clinic of North America. Lewis JH (ed) W.B. Saunders, Philadelphia 1995; 875-905.
43. Seeff LB: Acute viral hepatitis, In Liver and Biliary Diseases, 2nd Edition. Edited by N Kaplowitz; Williams & Wilkins, Baltimore 1996;289-316.
44. Seeff LB. Acute viral hepatitis, In Current Practice of Medicine, Edited by RC Bone and WC Maddrey, Churchill Livingstone, Inc., Philadelphia; 1996:XIV2.1-XIV2.8.
45. Seeff LB. Diagnosis, therapy, and prognosis of viral hepatitis. In Hepatology. A Textbook of Liver Disease, Third Edition. Edited by D Zakim and TD Boyer. WB Saunders Company, Philadelphia 1996;1067-1145.
46. Seeff LC, Seeff LB. Pulmonary disorders and the liver. In The Liver and Systemic Disease. N. Gitlin (ed). Churchill Livingstone, New York, 1997:17-42.
47. Seeff LB, Johnson M. Understanding hepatitis. National Hemophilia Foundation Publication. 1977:1-21.
48. Seeff LB. The natural history of chronic hepatitis C virus infection. In Clinics in Liver Disease. G. Davis, Guest Editor, WB Saunders Company, Philadelphia, 1997;1:587- 602.
49. Pham DQ, Seeff LB. Acute hepatitis: Management and prevention in current therapy in adult Medicine. JP Kassirer, Harry C. Greene (eds). Moskay, St. Louis 1997;707-711.
50. Strader DB, Seeff LB. Drug-induced chronic liver disease. In Clinics in Liver Disease. M. Black, Guest Editor, WB Saunders Company, Philadelphia, 1998;2:501-522.
51. Alter HJ, Seeff LB: Transfusion-associated hepatitis. In: Viral Hepatitis, Second Edition. AJ Zuckerman and HC Thomas (eds). Churchill Livingstone, London, 1998:489-514.
52. Seeff LB. Acute viral hepatitis, In: Current practice of Medicine, edited by FL Fitzgerald. 1999;2:1-7
53. Seeff LB. Natural history of hepatitis C, In: Liver disease, edited by JK Liang and JH
Hoofnagle. Academic Press, San Diego 2000:85-105.

ABSTRACTS:
1. LB Seeff, HJ Zimmerman, EC Wright and Members of Cooperative Study Group, VA
Hospital, Washington, D.C., Eastern Cooperative Study Center, West Haven, Connecti-cut. VA Cooperative Study of Gamma Globulin Prophylaxis of Post Transfusion Hepatitis. Gastroenterology 64:A-207/893, 1973.
2. HO Conn, CM Leevy, WC Maddrey, JB Rodgers, LB Seeff, ZR Vlahcevic: Lactulose in the Treatment of Chronic Portal-Systemic Encephalopa-thy: A Prospective Double-Blind Cooperative Comparison of Lactulose and Neomycin. Gastroenterology 67:784,1974.
3. HB Greenlee, AA Dietz, LB Seeff, JH Zimmerman, EC Wright and Members of VA Hepatitis Cooperative Study Group, VA Hospital, Hines, Illinois and VA Hospital, Washington, DC: Reduction in Incidence of Post-transfusion Hepatitis Following Conversion to Volunteer Donors. Gastroenterology 69:A25/825, 1975.
4. LB Seeff, EC Wright, JH Alter, VJ McAuliffe, P Kaplan, JL Gerin, RH Purcell, PV Holland, HJ Zimmerman, Members of the VA Hepatitis Cooper-ative Studies Group. e Antigen (e) and DNA Polymerase (DNAP): Rela-tionship to the Infectivity of HBsAg-Positive Blood and the Efficacy of Hepatitis B Immune Globulin (HBIG). Gastroenterology 71:A35/928, 1976.
5. HJ Alter, LB Seeff, PM Kaplan, et al: Hepatitis B Specific DNA Polymerase and e Antigen as Indicators of the Infectivity of Human Blood: Implications for Clinical Trials of Hepatitis B Immune Globulin. Presented at the American Association of Blood Banks 29th Annual Meeting, Los Angeles, California, November 1976.
6. JH Hoofnagle, LB Seeff, ZB Bales, HJ Zimmerman, and the Veterans Administration (VA) Hepatitis Cooperative Study Group. VA Hospital, Washington, D.C.: Type B Hepatitis After Transfusion with Blood Positive for Antibody to Hepatitis B Core Antigen (Anti-HBc). Gastroen-terology 74:1157, 1978.
7. Hoofnagle JH, Seeff LB, Bales ZB, Zimmerman, HJ: Mechanism of action of hepatitis B Immune globulin (HBIG) and immune serum globulin. Gastroenter-ology 76:1284,1979.
8. Altman RS, Brook I, Loebman WW, Seeff LB: Ascitic fluid lactic acid (LA) levels: A valuable test for the diagnosis of bacterial peritonitis (BP), particularly spontaneous bacterial peritoni-tis (SBP) of cirrho-sis. Gastroenterology 79:1026, 1980.
9. Hoofnagle JH, Seeff LB, Dusheiko GM, Jones EA: Seroconversion from hepatitis B e antigen to antibody during chronic type B hepatitis. Gastroenterology 79:1026,1980.
10. Idhe DC, Matthews MJ, Seeff LB, Bunn PA, Cohen MH, Minna JD: "Long-term" survivors (LTS) in Doxorubicin-treated pa-tients with hepatocellular carcinoma (HC). Presented at 72nd annual meeting of the American Association for Cancer Re-search, Washington, DC, April/May 1981.
11. Hall RP, Hoofnagle JH, Dusheiko GM, Seeff L, Hawley, TJ: Circulating immune complexes in acute viral hepatitis. Clin. Res. 29:307A, 1981.
12. Rubel LR, Rabin L, Seeff LB, Licht H, Zimmerman, HJ: Primary biliary cirrhosis in man. Lab. Invest. 46:71A, 1982.
13. Stern W, Steel L, Haye O, Chandra M, Patterson R, Kaline M, Nashel D, Seeff LB. Catravas G: Effects of aspirin and acetaminophen on human gastric an duodenal muscosa: evaluation by endoscopy, histology and prostaglandin assay. Amer. J. Gastroenterology 77;695, 1982.
-14. Abernathy CO, Seeff LB, Zimmerman HJ, Utili R, Gaeta GB, Ardinolgi LE: Potentiation of ethanol (ETOH)-induced narcosis in mice by pretreat-ment with bacterial lypopolysaccharide (LPS). Hepatology 2:731A, 1982.
15. Eichberg JW, Seeff LB, Goldstein AL, Lawler DA, Buskell-Bales Z, Ishak KG: Immuno-therapy of chimpanzee hepatitis B carriers: Clinical and cellular immune responses. In -Viral Hepatitis- -and Liver Disease.- GN Vyas, JL Dienstag, JH Hoofnagle (eds.). Grune and Stratton, Inc., Orlando, 1984, p648.
16. Seeff LB, Buskell-Bales Z, Cuccherini B, Hoofnagle JH, Beebe G, Norman J: 1942 Yellow-fever vaccine-associated hepatitis among U.S. Ser-vicemen. In -Viral Hepatitis and Liver Disease.- GN Vyas, JL Dienstag, and JH Hoofnagle (eds.). Grune and Stratton, Inc., Orlando, 1984, p. 645.
17. Buskell-Bales Z, Seeff LB: Nationwide prevalence of anti-HBs among Veterans Administration employees. In -Viral Hepatitis and Liver- -Disease.- GN Vyas, J.L. Dienstag, and JH Hoofnagle (eds.). Grune and Stratton, Inc., Orlando, 1984 p.645.
18. Ponzetto A, Hoofnagle HJ, Seeff LB: Antibody to delta agent in immune serum globulins. In -Viral Hepatitis and Liver Disease.- GN Vyas, JL Dienstag, and JH Hoofnagle (eds.). Grune and Stratton, Inc., Orlando, 1984, p615.
19. Seeff LB, Beebe GW, Norman JE, Buskell-Bales Z, Hoofnagle JH: Sero-logic follow-up of 1942 yellow-fever vaccine-associated hepati-tis outbreak. Hepatology 5:959, 1985.
20. Hoofnagle JH, Davis GL, Hanson RG, Avigan M, Peters MG, Pappas SC, Seeff LB, Jones EA: Randomized double-blind placebo-controlled trial of a one month course of predinisolone in chronic type B hepatitis. Gastroenter-ology 1984; 86:1324.
21. Epstein MS, Ingram CW, Borts FT, Korman LY, Seeff LB: Retrospective and prospective analysis of focal liver defects (FLD) demonstrated by computerized tomography(CT). Gastroenterology.
22. Sjogren MH, Seeff LB, Hoofnagle JH, Bales ZB, Beebe GW, Norman, JE: Persistence of IgM anti-HBc more than 40 years after hepatitis B virus infection. J Med Virol 1987;21:1A.
23. Joung NK, Seeff LB, Buskell-Bales Z: Does perinatal HBV prophylaxis prevent the transmission of NANB hepatitis? Hepatology 1988; 3:1329.
24. Yudelman P, Wilensky RL, Goodman ZD, Seeff LB, Atkinson J, Roberts WC: Hepatic changes in idiopathic dilated cardiomyopathy. Hepatology 1988;8:1333.
25. Seeff LB, and the NHLBI study group. Mortality of non-A, non-B trans-fusion- associat-ed hepatitis (NANB TAH) in the U.S. 15 years after transfusion. Hepatology 1991;14:90A.
26. Gibert C, Bales Z, Nugent R, Seeff LB, Gordin F. Seroepidemiology of hepatitis C virus (HCV) in unselected admissions to an inner city hospital. Presented at 32nd ICAAC, Annaheim, California, May 1992.
27. Blosser A, Seeff LB. Delayed fulminant Bactrim hepatotoxicity in an immunocompromised patient. American College of Gastroen-terology, Miami Beach, Fla, 1992.
28. Gibert CL, Walshe DK, Bales Z, Seeff LB, Gordin FM. Seroepidemiology of hepatitis C virus (HCV) in an HIV-infected inner city hospital population. IXth International Conference on AIDS, Berlin, June 1993.
29. Seeff LB and the NHLBI Study Group. Sequelae of transfusion-associated non-A, non-B hepatitis. Fourth International Symposium on HCV. Tokyo, May 1993.
30. Gibert CL, Walshe DK, Montgomery JR, Pham J, Hill JH, Lokken G, Buskell-Bales Z, Collier K, and Seeff LB. The Prevalence of Syphilis Seroreactivity in Unselected Admissions to an Inner City Hospital. The 34th ICAAC. Orlando. October 1994.
31. Seeff LB, Buskell-Bales ZJ, and the NHLBI Study Group. Mortality and Morbidity of Transfusion-Associated Type C Hepatitis : An NHLBI Multi-Center Study. Hepatology, 1994;20:204A
32. Pham D, Walshe D, Montgomery J, Buskell-Bales Z, Collier K, Lokken G, Claggett J, Wilson L, Biswas R, Gibert C, and Seeff LB. Seroepidemiology of Hepatitis C and B in an Urban VA Medical Center. Hepatology 1994;20:326A.
33. Pham DQ, Montgomery J, Buskell-Bales Z, Claggett J, Wilson L, Biswas R, and Seeff LB. Specificity of Second-Generation Enzyme-Linked Immunoas-say (EIA) in the Diagnosis of Hepatitis C Virus (HCV) Infection. The American Association for the Study of Liver Diseases. Chicago. November 1994.
34. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Mahaney K, Seeff, LB. Tolerance and efficacy of oral Ribavirin for treatment of chronic hepatitis C a multi-center study. Hepatology 1994;20:207A
35. Kerr GS, Rofail MZ, Lewis JH, Hallahan, C, Seeff, LB. A prospective case-controlled study of the prevalence of hepatitis C (HCV)-related cryoglobulinemia (cryo) at an inner city hospital. Gastroenterology, May 1995.
36. Rofail MZ, Kerr GS, Lewis JH, Kalloo D,Buskell-Bales Z, Seeff, LB. Response of hepatitis C virus (HCV) cryoglobuli-nemia (cryo) to alpha interferon 2 b (IFN). Gastroenterology, 1995.
37. Rofail MZ, Lewis JH, Seeff, LB. pruritis and chronic hepatitis C. Gastroenterology, 1995.
38. Rofail MZ, Lewis JH, Kalloo D, Buskell-Bales Z, Seeff LB. Interferon (IFN) treatment of patients with chronic hepatitis C virus (HCV) infection with mildly elevated serum enzymes. Gastroenterology, May 1995.
39. Fiel M, Guido M, Thung SN, Lindsay KL, Davis GL, Lewis JH, Seeff LB, Bodenheimer Jr,HC. Hepatic iron depletion during ribavirin therapy of chronic hepatitis C. Hepatology 1995; 22:290.
40. Wright EC, Seeff LB, Buskell-Bales Z, Durako S, Cain C, and the NHLBI Transfusion- Associated Hepatitis Study Group. Multi-Center Trials and Cohort Studies--Unanticipated Resources for Long-Term Studies of Disease Outcomes. Society for Clinical Trials Inc, Pittsburgh, PA, May 1996.
41. Nourjah P, Wright DJ, Korelitz JJ, Cain CMB, Wright EC, Seeff LB, and the NHLBI Transfusion-Associated Hepatitis Study Group. An Application of Capture-Recapture Methods to Adjust for Incomplete Case Ascertainment: The Effect of Misclassification Bias. Society for Epidemiology Research, Pittsburgh, PA, May 1996.
42. Hollinger FB, Wright L, Buskell-Bales Z, Seeff LB, and the NHLBI Study Group. Natural History of Transfusion-Associated Hepatitis (TAH) C: An NHLBI Multi-Center Study. IX Triennial International Symposium on Viral Hepatitis and Liver Disease. Rome, Italy, April 1996.
43. Tedeschi V, Bales ZB, Kalloo D, Maertens G, Seeff LB. HCV genotypes among consecutive hospital admissions to a United States urban VA Medical Center. Gastroenterology 1995;108:A1184
44. Kerr G, Rofail MZ, Lewis JH, Hallahan C, Seeff LB. A prospective, case-controlled study of the prevalence of hepatitis C virus (HCV)-related cryoglobulinemia (CRYO) at an inner city hospital. Arthritis Rheum 1995;38:R20.
45. Wright EC, Seeff LB, Hollinger FB, Alter HJ, Buskell-Bales Z, Cain C and the NHLBI Study Group. Updated long-term mortality of transfusion-associated hepatitis (TAH) non-A, Non- B and C. Hepatology 1998;28:272A
46. Seeff LB, Miller RN, Rabkin CS, Bales ZB, Smoak BL, Johnson LD, Kaplan EL. 45-50 year follow-up of hepatitis C virus (HCV) infection among young military recruits. Hepatology
1998;28:360A.
47. Seeff LB, Hollinger FB, Alter HJ, Wright EC, Bales ZB, and the NHLBI Study Group. Long- term morbidity of transfusion-associated hepatitis (TAH) C. Hepatology 1998; 28:407A
48. Yeh MM, Wright E, Seeff L, Strader D, Buskell-Bales Z, Goodman Z. The changing
histologic features of chronic hepatitis C in IV drug abusers – 1970’s vs 1990’s. Modern Pathology 2001;14:205A
49. Laskus T, Wilkinson J, Radkowski M, Adair D, Buskell Z, Seeff L, Rakela J. HCV
quasispecies transmission in acute hepatitis C in patients infected via blood
transfusion. Hepatology 2001;34:217A.
50. Strader DB, Korman L, Sharma A, Dufour DR, Seeff LB. Combination interferon/ribavirin
therapy is associated with a poor response and high complication rate among African-
American (AA) veterans. Hepatology 2001;34:334A.

LETTERS:
1. Pereria W, Seeff LB: Sudden Scrotal Edema. Old pearls. Annals Int. Med. 75:647, October 1971.
2. Seeff LB, Zimmerman HJ, Wright EC, et al: Rates of post-transfusion hepatitis. New Engl. J. Med. 292:532, 1975.
3. Seeff LB, Zimmerman HJ, Wright EC, Gocke DJ, Aach RD: Infectivity of blood contain-ing hepatitis B antibody. Lancet 1:528-529, 1975.
4. Seeff LB, Zimmerman HJ, Wright EC: Gamma globulin and non-A type hepatitis. Ann. Int. Med. 89:141-143, 1978.
5. Hoofnagle JH, Seeff LB: Prevention of hepatitis with gamma globulin. Ann. Int.Med. 92:868-870, 1980.
6. Tabor E, Snoy P, Gerety RJ, Wickerhouser M, Menache D, Seeff LB: Transmission of agent of post-transfusion Non-A, Non-B hepatitis by cryoprecipitate prepared from plasma of symptomatic chronic carriers. Lancet 1:63-64, 1983.
7. Rubel LR, Seeff LB, Patel L: Primary biliary cirrhosis-primary sclerosing cholangi-tis overlap syndrome. Arch. Pathol. Lab. Med. 1984; 108:360-361.
8. Seeff LB, Zimmerman HJ: Acetaminophen hepatotoxicity in alcoholics. Ann. Int.Med. 1986: 105;624-625.
9. Hoofnagle JH, Jones EA, Dusheiko GM, Seeff, LB: Seroconersion from hepatitis B e antigen in chronic type B hepatitis. Ann. Int. Med. 1981:95;656-657.
10. Seeff LB: Hepatitis C from a needlestick injury. Ann. Int. Med. 1991: 115-411.
11. Dufour DR, Ashwood ER, Nolte FS, Seeff LB. More on viral hepatitis. Amer J Clin Pathol 2000;114:660-664.

BOOKS:
1. Current Perspectives in Hepatology: A Festschrift for Hyman J. Zimmerman, M.D., edited by LB Seeff, JH Lewis. Plenum Medical, New York, 1989.
2. Seminars in Liver Disease: Hepatitis C. Guest Editor: Leonard B. Seeff -BOOK REVIEWS:
1. "Viral Hepatitis" by Dr. Raymond Koff. Gastroenterology 77:601, 1979.
2. Guidelines for Detection of Hepatotoxicity Due to Drugs and Chemicals. USDHEW (NIH), Public Health Service, Bethesda, Maryland. Gastroenter-ology 79:597 598, 1980.
3. "Anesthesia and the Patient with Liver Disease," edited by Dr. Burrell Brown, Gastroenterology 82:595, 1982.
4. "Viral Hepatitis: Laboratory and Clinical Science," edited by F. Deinhardt and J. Deinhardt; Marice Decker, Inc. Gastroenterology 1984; 87:1402-1403.
5. "Viral Hepatitis: Biological and Clinical Features, Specific Diagno-sis and Prophylax- is." Edited by F. Blaine Hollinger, Joseph Melnick, Williams Robinson, Raven Press. Hepatology 1986: 6:759-760.
6. "Drug-Induced Liver Disease". Farrell GC. Churchill Livingstone: New York, 1994. Gastroenterology. 1995;109:1716-1717.
7. "Liver Disease: Diagnosis and Management." Bacon BR and Di Bisceglie AM. New York, Churchill Livingstone. Ann Int Med 2000:133;316

IN PRESS:
Several papers.